Singapore: Temasek backs $20m Series A in bioengineering firm Medisix

T-lymphocytes attack a migrating cancer cell. Visual from Medisix's website.

Singapore-based MediSix Therapeutics, which is developing cellular therapies targeting T-cell leukaemia and lymphoma, announced that it has raised $20 million in Series A financing backed by state investment arm Temasek Holdings.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at